Valneva Shares Drop 5.65% at Midday, RSI Reaches Overbought Territory

Significant Midday Drop for VALNEVA

The VALNEVA stock shows a notable decline at midday this Monday, slipping to 4.14 euros after having closed at 4.39 euros on Friday. This 5.65% correction occurs in a context of high volatility, with only 0.36% of the capital traded since the opening. However, the stock remains well above its reference moving averages, trading 7% above its 50-day average and 17.3% above its 200-day average. Over the past year, the stock has shown a spectacular performance of nearly 100%, boosted by the clinical advancements of the IXCHIQ vaccine against chikungunya and the full recovery of commercialization rights in endemic countries at the beginning of January, following the end of the agreement with the Serum Institute of India. This progress is part of a European biotechnological sector that has been regaining color for several weeks.

RSI Indicates Overbought Condition

The Relative Strength Index stands at 79 points at midday, placing the stock in an overbought zone beyond the critical threshold of 70. This indicator suggests that the stock may undergo a technical consolidation phase after its recent surge, without indicating a trend reversal. The price still trades above the technical resistance threshold identified at 4.43 euros. On the analyst side, recommendations remain mixed: Stifel recently raised its price target from 9.50 to 10 euros at the beginning of January while maintaining its buy recommendation, whereas Goldman Sachs remains neutral with a target reduced to 3.25 euros at the end of November. Investors remain attentive to the results of the clinical trial on the Lyme disease vaccine, expected in the first half of 2026.